This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gilbar, P. J Articles by Carrington, C. V Search for Related Content PubMed PubMed Citation Articles by Gilbar, P. J Articles by Carrington, C. V Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags

Department of Pharmacy, Toowoomba Health Services, PMB 2, Toowoomba 4350, Australia

Christine V Carrington, BPharm (Hons), Dip Clin Pharm, MMedSciClinOncol

Department of Pharmacy, Mater Health Services, Raymond Terrace, South Brisbane 4101, Australia

Study objective. The aim of this retrospective study was to determine the incidence of vinca alkaloid extravasation following administration via syringes or mini-bags.

Methods. An electronic survey was sent to pharmacy departments at hospitals throughout Australia. The survey was designed to collect data on the administration methods of vinca alkaloids (vincristine, vinblastine, vinorelbine) and the corresponding documented incidence of extravasation. The questionnaire requested the following information: how the drugs were prepared for administration (syringe or mini-bag); volume of each product; number of items supplied; and the number of cases of extravasation reported for each product.

Results. Questionnaires were sent to 228 hospital pharmacy departments in Australia. Sixty-eight questionnaires were received (29.8%), including responses from most major cancer centres. Data represented a range of 3 to 120 months (mean: 38 months) of clinical experience. The reported incidence of vincristine extravasation from syringes was 0.03% (11/37 084) and 0.041% (3/7255) with mini-bags. One case of vinblastine extravasation was reported with syringes 0.013% (1/7913), none from mini-bags (0/1421). Vinorelbine data were difficult to interpret as cases may represent phlebitis rather than extravasation. The reported incidence from vinorelbine syringes was 0.029% (2/6914) and 0.146% (8/5475) with mini-bags. Excluding vinorelbine data, the reported vinca alkaloid extravasation episodes from syringes (0.027%) and mini-bags (0.035%) were found to be similar and infrequent.

Conclusion. The data suggest that vinca alkaloids can be given safely as low volume, short infusions via mini-bags. Policies and practices that ensure the same careful monitoring of infusional therapy as is recommended with administration by syringe may further reduce the incidence of untoward effects. Mini-bags should be used for the administration of vinca alkaloids and this practice will prevent the inadvertent intrathecal administration of vinca alkaloids via syringes.

Key Words: extravasation • inadvertent intrathecal administration • mini-bags • syringes • vinblastine • vinca alkaloid • vincristine • vinorelbine

Journal of Oncology Pharmacy Practice, Vol. 12, No. 2, 113-118 (2006)
DOI: 10.1177/1078155206070448


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?